Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells

Ussama M. Abdel-Motal, Heath M. Guay, Kim Wigglesworth, Raymond M. Welsh, Uri Galili

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

This study describes a method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-Gal antibody to effectively target vaccines to antigen-presenting cells (APC). This method is based on enzymatic engineering of carbohydrate chains on virus envelope hemagglutinin to carry the α-Gal epitope (Galα1-3Galβ1-4GlcNAc- R). This epitope interacts with anti-Gal, the most abundant antibody in humans (1% of immunoglobulins). Influenza virus vaccine expressing α-Gal epitopes is opsonized in situ by anti-Gal immunoglobulin G. The Fc portion of opsonizing anti-Gal interacts with Fcγ receptors on APC and induces effective uptake of the vaccine virus by APC. APC internalizes the opsonized virus to transport it to draining lymph nodes for stimulation of influenza virus-specific T cells, thereby eliciting a protective immune response. The efficacy of such an influenza vaccine was demonstrated in α1,3galaciosyltransferase (α1,3GT) knockout mice, which produce anti-Gal, using the influenza virus strain A/Puerto Rico/8/34-H1N1 (PR8). Synthesis of α-Gal epitopes on carbohydrate chains of PR8 virus (PR8αgal) was catalyzed by recombinant α1,3GT, the glycosylation enzyme that synthesizes α-Gal epitopes in cells of nonprimate mammals. Mice immunized with PR8 αgal displayed much higher numbers of PR8-specific CD8 + and CD4+ T cells (determined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 antibodies with much higher titers than mice immunized with PR8 lacking α-Gal epitopes. Mice immunized with PR8αgal also displayed a much higher level of protection than PR8 immunized mice after being challenged with lethal doses of live PR8 virus. We suggest that a similar method for increasing immunogenicity may be applicable to avian influenza vaccines.

Original languageEnglish
Pages (from-to)9131-9141
Number of pages11
JournalJournal of Virology
Volume81
Issue number17
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Puerto Rico
Influenza Vaccines
Antigen-Presenting Cells
Epitopes
H1N1 Subtype Influenza A Virus
Viruses
Vaccines
Carbohydrates
T-Lymphocytes
Enzyme-Linked Immunospot Assay
Influenza in Birds
Fc Receptors
Antibodies
Influenza A virus
Hemagglutinins
Orthomyxoviridae
Glycosylation
Knockout Mice
Immunoglobulins
Mammals

ASJC Scopus subject areas

  • Immunology

Cite this

Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. / Abdel-Motal, Ussama M.; Guay, Heath M.; Wigglesworth, Kim; Welsh, Raymond M.; Galili, Uri.

In: Journal of Virology, Vol. 81, No. 17, 09.2007, p. 9131-9141.

Research output: Contribution to journalArticle

Abdel-Motal, Ussama M. ; Guay, Heath M. ; Wigglesworth, Kim ; Welsh, Raymond M. ; Galili, Uri. / Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. In: Journal of Virology. 2007 ; Vol. 81, No. 17. pp. 9131-9141.
@article{bb5f52269f54465db61f7b0fb4875270,
title = "Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells",
abstract = "This study describes a method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-Gal antibody to effectively target vaccines to antigen-presenting cells (APC). This method is based on enzymatic engineering of carbohydrate chains on virus envelope hemagglutinin to carry the α-Gal epitope (Galα1-3Galβ1-4GlcNAc- R). This epitope interacts with anti-Gal, the most abundant antibody in humans (1{\%} of immunoglobulins). Influenza virus vaccine expressing α-Gal epitopes is opsonized in situ by anti-Gal immunoglobulin G. The Fc portion of opsonizing anti-Gal interacts with Fcγ receptors on APC and induces effective uptake of the vaccine virus by APC. APC internalizes the opsonized virus to transport it to draining lymph nodes for stimulation of influenza virus-specific T cells, thereby eliciting a protective immune response. The efficacy of such an influenza vaccine was demonstrated in α1,3galaciosyltransferase (α1,3GT) knockout mice, which produce anti-Gal, using the influenza virus strain A/Puerto Rico/8/34-H1N1 (PR8). Synthesis of α-Gal epitopes on carbohydrate chains of PR8 virus (PR8αgal) was catalyzed by recombinant α1,3GT, the glycosylation enzyme that synthesizes α-Gal epitopes in cells of nonprimate mammals. Mice immunized with PR8 αgal displayed much higher numbers of PR8-specific CD8 + and CD4+ T cells (determined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 antibodies with much higher titers than mice immunized with PR8 lacking α-Gal epitopes. Mice immunized with PR8αgal also displayed a much higher level of protection than PR8 immunized mice after being challenged with lethal doses of live PR8 virus. We suggest that a similar method for increasing immunogenicity may be applicable to avian influenza vaccines.",
author = "Abdel-Motal, {Ussama M.} and Guay, {Heath M.} and Kim Wigglesworth and Welsh, {Raymond M.} and Uri Galili",
year = "2007",
month = "9",
doi = "10.1128/JVI.00647-07",
language = "English",
volume = "81",
pages = "9131--9141",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "17",

}

TY - JOUR

T1 - Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells

AU - Abdel-Motal, Ussama M.

AU - Guay, Heath M.

AU - Wigglesworth, Kim

AU - Welsh, Raymond M.

AU - Galili, Uri

PY - 2007/9

Y1 - 2007/9

N2 - This study describes a method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-Gal antibody to effectively target vaccines to antigen-presenting cells (APC). This method is based on enzymatic engineering of carbohydrate chains on virus envelope hemagglutinin to carry the α-Gal epitope (Galα1-3Galβ1-4GlcNAc- R). This epitope interacts with anti-Gal, the most abundant antibody in humans (1% of immunoglobulins). Influenza virus vaccine expressing α-Gal epitopes is opsonized in situ by anti-Gal immunoglobulin G. The Fc portion of opsonizing anti-Gal interacts with Fcγ receptors on APC and induces effective uptake of the vaccine virus by APC. APC internalizes the opsonized virus to transport it to draining lymph nodes for stimulation of influenza virus-specific T cells, thereby eliciting a protective immune response. The efficacy of such an influenza vaccine was demonstrated in α1,3galaciosyltransferase (α1,3GT) knockout mice, which produce anti-Gal, using the influenza virus strain A/Puerto Rico/8/34-H1N1 (PR8). Synthesis of α-Gal epitopes on carbohydrate chains of PR8 virus (PR8αgal) was catalyzed by recombinant α1,3GT, the glycosylation enzyme that synthesizes α-Gal epitopes in cells of nonprimate mammals. Mice immunized with PR8 αgal displayed much higher numbers of PR8-specific CD8 + and CD4+ T cells (determined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 antibodies with much higher titers than mice immunized with PR8 lacking α-Gal epitopes. Mice immunized with PR8αgal also displayed a much higher level of protection than PR8 immunized mice after being challenged with lethal doses of live PR8 virus. We suggest that a similar method for increasing immunogenicity may be applicable to avian influenza vaccines.

AB - This study describes a method for increasing the immunogenicity of influenza virus vaccines by exploiting the natural anti-Gal antibody to effectively target vaccines to antigen-presenting cells (APC). This method is based on enzymatic engineering of carbohydrate chains on virus envelope hemagglutinin to carry the α-Gal epitope (Galα1-3Galβ1-4GlcNAc- R). This epitope interacts with anti-Gal, the most abundant antibody in humans (1% of immunoglobulins). Influenza virus vaccine expressing α-Gal epitopes is opsonized in situ by anti-Gal immunoglobulin G. The Fc portion of opsonizing anti-Gal interacts with Fcγ receptors on APC and induces effective uptake of the vaccine virus by APC. APC internalizes the opsonized virus to transport it to draining lymph nodes for stimulation of influenza virus-specific T cells, thereby eliciting a protective immune response. The efficacy of such an influenza vaccine was demonstrated in α1,3galaciosyltransferase (α1,3GT) knockout mice, which produce anti-Gal, using the influenza virus strain A/Puerto Rico/8/34-H1N1 (PR8). Synthesis of α-Gal epitopes on carbohydrate chains of PR8 virus (PR8αgal) was catalyzed by recombinant α1,3GT, the glycosylation enzyme that synthesizes α-Gal epitopes in cells of nonprimate mammals. Mice immunized with PR8 αgal displayed much higher numbers of PR8-specific CD8 + and CD4+ T cells (determined by intracellular cytokine staining and enzyme-linked immunospot assay) and produced anti-PR8 antibodies with much higher titers than mice immunized with PR8 lacking α-Gal epitopes. Mice immunized with PR8αgal also displayed a much higher level of protection than PR8 immunized mice after being challenged with lethal doses of live PR8 virus. We suggest that a similar method for increasing immunogenicity may be applicable to avian influenza vaccines.

UR - http://www.scopus.com/inward/record.url?scp=34548157925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548157925&partnerID=8YFLogxK

U2 - 10.1128/JVI.00647-07

DO - 10.1128/JVI.00647-07

M3 - Article

VL - 81

SP - 9131

EP - 9141

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 17

ER -